Evommune EVMN 深 沪
等待开盘 05-21 09:30:00 美东时间
22.28
+1.160
+5.49%
华盛通- 最 高22.42
- 今 开21.36
- 成交量 35.38万股
- 最 低 21.26
- 昨 收 21.12
- 总市值 8.02亿
- 52周最高 33.20
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 13.885
- 委 比 0.00%
- 总股本 3601.84万
- 历史最高 33.20
- 量 比 0.88
- 振 幅 5.49%
- 历史最低 13.885
- 每 手 1
- 风险率 3.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Morgan Stanley Maintains Overweight on Evommune, Raises Price Target to $55
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and raises the price target from $54 to $55.
05-12 01:11
Evommune Q1 EPS $(0.64) Beats $(0.71) Estimate
Evommune (NYSE:EVMN) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.71) by 9.86 percent.
05-08 04:38
Evommune Files Prospectus For Resale Of Up To 4,494,279 Shares Of Common Stock By Selling Stockholders
Up to 4,494,279 Shares of Common StockThis prospectus relates to the resale from time to time of up to 4,494,279 shares of common stock, par value $0.0001 per share (the "Shares"), of Evommune, Inc. by the selling
04-18 04:11
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
RBC Capital Reiterates Outperform on Evommune, Maintains $48 Price Target
RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintains $48 price target.
04-10 22:04
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright & Co, Stifel, BTIG, Goldman Sachs made changes.
03-18 20:19
Clear Street Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $53
Clear Street analyst Kaveri Pohlman initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $53.
03-18 17:25
Evommune shares are trading higher. The company reported Q4 financial results.
Evommune shares are trading higher. The company reported Q4 financial results.
03-07 01:36
